William Blair analyst Sami Corwin has maintained their bullish stance on KYTX stock, giving a Buy rating today.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sami Corwin’s rating is based on the promising interim results from Kyverna Therapeutics’ Phase II KYSA-6 trial for KYV-101 in treating generalized myasthenia gravis (gMG). The trial demonstrated that 100% of patients showed clinically meaningful responses while discontinuing immunomodulators, highlighting the drug’s durable efficacy and clear differentiation from existing therapies.
Furthermore, the trial results indicated significant improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores as early as two weeks into treatment. Additionally, the safety profile of KYV-101 was deemed tolerable, with only low-grade cytokine release syndrome (CRS) reported and no cases of immune effector cell-associated neurotoxicity syndrome (ICANS). These positive outcomes contribute to the de-risking of the upcoming Phase III trial, supporting the Buy rating.
In another report released today, Wells Fargo also maintained a Buy rating on the stock with a $31.00 price target.